Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium

R L Grossman¹, B Abel², S Angiuoli³, J C Barrett⁴, D Bassett⁵, K Bramlett⁶, G M Blumenthal⁷, A Carlsson⁸, R Cortese⁹, J DiGiovanna⁹, B Davis-Dusenbery⁹, R Dittamore¹⁰, D A Eberhard², P Febbo², M Fitzsimons¹, Z Flamig¹, J Godsey¹¹, J Goswami¹², A Gruen⁹, F Ortuño¹, J Han², D Hayes¹³, J Hicks⁸, D Holloway⁹, D Hovelson¹³, J Johnson⁴, H Juhl¹⁴, R Kalamegham¹⁵, R Kamal¹⁶, Q Kang¹³, G J Kelloff¹⁷, M Klozenbuecher¹⁶, A Kolatkar⁸, P Kuhn⁸, K Langone², R Leary¹⁸, P Loverso³, H Manmathan⁹, A-M Martin¹⁹, J Martini²⁰, D Miller¹, M Mitchell²¹, T Morgan¹³, R Mulpuri²², T Nguyen¹, G Otto²³, A Pathak²⁴, E Peters²⁵, R Philip²⁴, E Posadas^{26

27}, D Reese²², M G Reese¹⁶, D Robinson¹⁸, A Dei Rossi², H Sakul²⁰, J Schageman⁶, S Singh²³, H I Scher²¹, K Schmitt¹, A Silvestro¹⁸, J Simmons³, T Simmons¹, J Sislow¹, A Talasaz²⁸, P Tang¹, M Tewari¹³, S Tomlins¹³, H Toukhy²⁸, H R Tseng^{26

29}, M Tuck¹³, A Tzou²⁴, J Vinson²¹, Y Wang¹⁰, W Wells³⁰, A Welsh²³, J Wilbanks³¹, J Wolf²², L Young²³, Jsh Lee¹⁷, L C Leiman³²

Affiliations

¹ Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA.
² Genomic Health, Redwood City, California, USA.
³ Personal Genome Diagnostics, Baltimore, Maryland, USA.
⁴ AstraZeneca, Waltham, Massachusetts, USA.
⁵ Celgene, Seattle, Washington, USA.
⁶ Thermo Fisher Scientific, Austin, Texas, USA.
⁷ Center for Drug Evaluation and Research, Food and Drug Administration, Silver Springs, Maryland, USA.
⁸ Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA.
⁹ Seven Bridges, Cambridge, Massachusetts, USA.
¹⁰ Epic Research and Diagnostics, San Diego, California, USA.
¹¹ Thermo Fisher Scientific, Waltham, Massachusetts, USA.
¹² Thermo Fisher Scientific, Carlsbad, California, USA.
¹³ University of Michigan, Ann Arbor, Michigan, USA.
¹⁴ Indivumed GmbH, Hamburg, Germany.
¹⁵ Genentech, Washington, District of Columbia, USA.
¹⁶ Omicia, Oakland, California, USA.
¹⁷ Office of the Director, National Cancer Institute, Bethesda, Maryland, USA.
¹⁸ Novartis Institute for Biomedical Research, Cambridge, Massachusetts, USA.
¹⁹ Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
²⁰ Pfizer, San Diego, California, USA.
²¹ Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²² Provista Diagnostics Inc., New York, New York, USA.
²³ Foundation Medicine, Cambridge, Massachusetts, USA.
²⁴ Center for Device and Radiological Health, Food and Drug Administration, Silver Springs, Maryland, USA.
²⁵ Genentech, South San Francisco, California, USA.
²⁶ CytoLumina, Inc., Los Angeles, California, USA.
²⁷ Cedar-Sinai Medical Center, Los Angeles, California, USA.
²⁸ Guardant Health, Inc., Redwood City, California, USA.
²⁹ Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA.
³⁰ Open Commons Consortium, Chicago, Illinois, USA.
³¹ Sage Bionetworks, Seattle, Washington, USA.
³² BloodPAC, Chicago, Illinois, USA.

PMID: 28187516
PMCID: PMC5525192
DOI: 10.1002/cpt.666

Review

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium

R L Grossman et al. Clin Pharmacol Ther. 2017 May.

. 2017 May;101(5):589-592.

doi: 10.1002/cpt.666. Epub 2017 Apr 12.

Authors

Affiliations

¹ Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA.
² Genomic Health, Redwood City, California, USA.
³ Personal Genome Diagnostics, Baltimore, Maryland, USA.
⁴ AstraZeneca, Waltham, Massachusetts, USA.
⁵ Celgene, Seattle, Washington, USA.
⁶ Thermo Fisher Scientific, Austin, Texas, USA.
⁷ Center for Drug Evaluation and Research, Food and Drug Administration, Silver Springs, Maryland, USA.
⁸ Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA.
⁹ Seven Bridges, Cambridge, Massachusetts, USA.
¹⁰ Epic Research and Diagnostics, San Diego, California, USA.
¹¹ Thermo Fisher Scientific, Waltham, Massachusetts, USA.
¹² Thermo Fisher Scientific, Carlsbad, California, USA.
¹³ University of Michigan, Ann Arbor, Michigan, USA.
¹⁴ Indivumed GmbH, Hamburg, Germany.
¹⁵ Genentech, Washington, District of Columbia, USA.
¹⁶ Omicia, Oakland, California, USA.
¹⁷ Office of the Director, National Cancer Institute, Bethesda, Maryland, USA.
¹⁸ Novartis Institute for Biomedical Research, Cambridge, Massachusetts, USA.
¹⁹ Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
²⁰ Pfizer, San Diego, California, USA.
²¹ Memorial Sloan Kettering Cancer Center, New York, New York, USA.
²² Provista Diagnostics Inc., New York, New York, USA.
²³ Foundation Medicine, Cambridge, Massachusetts, USA.
²⁴ Center for Device and Radiological Health, Food and Drug Administration, Silver Springs, Maryland, USA.
²⁵ Genentech, South San Francisco, California, USA.
²⁶ CytoLumina, Inc., Los Angeles, California, USA.
²⁷ Cedar-Sinai Medical Center, Los Angeles, California, USA.
²⁸ Guardant Health, Inc., Redwood City, California, USA.
²⁹ Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA.
³⁰ Open Commons Consortium, Chicago, Illinois, USA.
³¹ Sage Bionetworks, Seattle, Washington, USA.
³² BloodPAC, Chicago, Illinois, USA.

PMID: 28187516
PMCID: PMC5525192
DOI: 10.1002/cpt.666

Abstract

The cancer community understands the value of blood profiling measurements in assessing and monitoring cancer. We describe an effort among academic, government, biotechnology, diagnostic, and pharmaceutical companies called the Blood Profiling Atlas in Cancer (BloodPAC) Project. BloodPAC will aggregate, make freely available, and harmonize for further analyses, raw datasets, relevant associated clinical data (e.g., clinical diagnosis, treatment history, and outcomes), and sample preparation and handling protocols to accelerate the development of blood profiling assays.

PubMed Disclaimer

Figures

See this image and copyright information in PMC

References

1. White House (US) . Remarks by the President in State of the Union Address [Internet]. Washington, DC: White House (US); [cited 06 February 2016]. Available from: <https://obamawhitehouse.archives.gov/the‐press‐office/2015/01/20/remarks...> (2015).
1. cobas EGFR Mutation Test v2, June 2, 2016 [cited 06 February 2016]. Available from: <http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm504540.htm>.
1. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) [cited 06 February 2016]. Available from: <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDi...>.
1. Parkinson, D.R. et al Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med. 10, 138–157 (2012). - PMC - PubMed
1. Parkinson, D.R. et al Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin. Cancer Res. 20, 1428–1444 (2014). - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium

Affiliations

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources